Skip to main content
Erschienen in: Acta Neuropathologica 1/2017

17.10.2016 | Original Paper

eEF2K inhibition blocks Aβ42 neurotoxicity by promoting an NRF2 antioxidant response

verfasst von: Asad Jan, Brandon Jansonius, Alberto Delaidelli, Syam Prakash Somasekharan, Forum Bhanshali, Milène Vandal, Gian Luca Negri, Don Moerman, Ian MacKenzie, Frédéric Calon, Michael R. Hayden, Stefan Taubert, Poul H. Sorensen

Erschienen in: Acta Neuropathologica | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Soluble oligomers of amyloid-β (Aβ) impair synaptic plasticity, perturb neuronal energy homeostasis, and are implicated in Alzheimer’s disease (AD) pathogenesis. Therefore, significant efforts in AD drug discovery research aim to prevent the formation of Aβ oligomers or block their neurotoxicity. The eukaryotic elongation factor-2 kinase (eEF2K) plays a critical role in synaptic plasticity, and couples neurotransmission to local dendritic mRNA translation. Recent evidence indicates that Aβ oligomers activate neuronal eEF2K, suggesting a potential link to Aβ induced synaptic dysfunction. However, a detailed understanding of the role of eEF2K in AD pathogenesis, and therapeutic potential of eEF2K inhibition in AD, remain to be determined. Here, we show that eEF2K activity is increased in postmortem AD patient cortex and hippocampus, and in the hippocampus of aged transgenic AD mice. Furthermore, eEF2K inhibition using pharmacological or genetic approaches prevented the toxic effects of Aβ42 oligomers on neuronal viability and dendrite formation in vitro. We also report that eEF2K inhibition promotes the nuclear factor erythroid 2-related factor (NRF2) antioxidant response in neuronal cells, which was crucial for the beneficial effects of eEF2K inhibition in neurons exposed to Aβ42 oligomers. Accordingly, NRF2 knockdown or overexpression of the NRF2 inhibitor, Kelch-Like ECH-Associated Protein-1 (Keap1), significantly attenuated the neuroprotection associated with eEF2K inhibition. Finally, genetic deletion of the eEF2K ortholog efk-1 reduced oxidative stress, and improved chemotaxis and serotonin sensitivity in C. elegans expressing human Aβ42 in neurons. Taken together, these findings highlight the potential utility of eEF2K inhibition to reduce Aβ-mediated oxidative stress in AD.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
4.
Zurück zum Zitat Boyce M, Py BF, Ryazanov AG, Minden JS, Long K, Ma D et al (2008) A pharmacoproteomic approach implicates eukaryotic elongation factor 2 kinase in ER stress-induced cell death. Cell Death Differ 15:589–599. doi:10.1038/sj.cdd.4402296 CrossRefPubMed Boyce M, Py BF, Ryazanov AG, Minden JS, Long K, Ma D et al (2008) A pharmacoproteomic approach implicates eukaryotic elongation factor 2 kinase in ER stress-induced cell death. Cell Death Differ 15:589–599. doi:10.​1038/​sj.​cdd.​4402296 CrossRefPubMed
8.
Zurück zum Zitat Carrera I, Etcheverria I, Li Y, Fernandez-Novoa L, Lombardi V, Vigo C et al (2013) Immunocytochemical characterization of Alzheimer disease hallmarks in APP/PS1 transgenic mice treated with a new anti-amyloid-beta vaccine. Biomed Res Int 2013:709145. doi:10.1155/2013/709145 CrossRefPubMedPubMedCentral Carrera I, Etcheverria I, Li Y, Fernandez-Novoa L, Lombardi V, Vigo C et al (2013) Immunocytochemical characterization of Alzheimer disease hallmarks in APP/PS1 transgenic mice treated with a new anti-amyloid-beta vaccine. Biomed Res Int 2013:709145. doi:10.​1155/​2013/​709145 CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Chen Z, Gopalakrishnan SM, Bui MH, Soni NB, Warrior U, Johnson EF et al (2011) 1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor. J Biol Chem 286:43951–43958. doi:10.1074/jbc.M111.301291 CrossRefPubMedPubMedCentral Chen Z, Gopalakrishnan SM, Bui MH, Soni NB, Warrior U, Johnson EF et al (2011) 1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor. J Biol Chem 286:43951–43958. doi:10.​1074/​jbc.​M111.​301291 CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101–112. doi:10.1038/nrm2101 CrossRefPubMed Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101–112. doi:10.​1038/​nrm2101 CrossRefPubMed
15.
Zurück zum Zitat Hamilton A, Vasefi M, Vander Tuin C, McQuaid RJ, Anisman H, Ferguson SS (2016) Chronic pharmacological mGluR5 inhibition prevents cognitive impairment and reduces pathogenesis in an alzheimer disease mouse model. Cell Rep 15:1859–1865. doi:10.1016/j.celrep.2016.04.077 CrossRefPubMed Hamilton A, Vasefi M, Vander Tuin C, McQuaid RJ, Anisman H, Ferguson SS (2016) Chronic pharmacological mGluR5 inhibition prevents cognitive impairment and reduces pathogenesis in an alzheimer disease mouse model. Cell Rep 15:1859–1865. doi:10.​1016/​j.​celrep.​2016.​04.​077 CrossRefPubMed
20.
22.
Zurück zum Zitat Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA et al (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13:159–170CrossRefPubMed Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA et al (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13:159–170CrossRefPubMed
27.
Zurück zum Zitat Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M et al (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448–6453CrossRefPubMedPubMedCentral Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M et al (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448–6453CrossRefPubMedPubMedCentral
38.
41.
Zurück zum Zitat Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R et al. (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39:409–421. doi:S0896627303004343 [pii] Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R et al. (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39:409–421. doi:S0896627303004343 [pii]
43.
Zurück zum Zitat Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, Livrea P et al (2005) Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. JNeurosci 25:11061–11070CrossRef Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, Livrea P et al (2005) Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. JNeurosci 25:11061–11070CrossRef
49.
Zurück zum Zitat Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP et al (2005) Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer’s disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18:602–617. doi:10.1016/j.nbd.2004.10.022 CrossRefPubMed Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP et al (2005) Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer’s disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18:602–617. doi:10.​1016/​j.​nbd.​2004.​10.​022 CrossRefPubMed
50.
51.
52.
Zurück zum Zitat Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766PubMed Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766PubMed
55.
Zurück zum Zitat Selkoe DJ, Schenk D (2003) Alzheimer’s disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43:545–584CrossRefPubMed Selkoe DJ, Schenk D (2003) Alzheimer’s disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43:545–584CrossRefPubMed
58.
Zurück zum Zitat Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800CrossRefPubMed Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800CrossRefPubMed
63.
Zurück zum Zitat Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A et al (1999) Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. JBiolChem 274:25945–25952 Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A et al (1999) Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. JBiolChem 274:25945–25952
64.
Zurück zum Zitat Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B et al (2002) Soluble oligomers of beta amyloid (1–42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924:133–140. doi:10.1016/S0006-8993(01)03058-X CrossRefPubMed Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B et al (2002) Soluble oligomers of beta amyloid (1–42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924:133–140. doi:10.​1016/​S0006-8993(01)03058-X CrossRefPubMed
67.
Zurück zum Zitat Wu Y, Wu Z, Butko P, Christen Y, Lambert MP, Klein WL et al (2006) Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci 26:13102–13113. doi:10.1523/JNEUROSCI.3448-06.2006 CrossRefPubMed Wu Y, Wu Z, Butko P, Christen Y, Lambert MP, Klein WL et al (2006) Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci 26:13102–13113. doi:10.​1523/​JNEUROSCI.​3448-06.​2006 CrossRefPubMed
Metadaten
Titel
eEF2K inhibition blocks Aβ42 neurotoxicity by promoting an NRF2 antioxidant response
verfasst von
Asad Jan
Brandon Jansonius
Alberto Delaidelli
Syam Prakash Somasekharan
Forum Bhanshali
Milène Vandal
Gian Luca Negri
Don Moerman
Ian MacKenzie
Frédéric Calon
Michael R. Hayden
Stefan Taubert
Poul H. Sorensen
Publikationsdatum
17.10.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Acta Neuropathologica / Ausgabe 1/2017
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-016-1634-1

Weitere Artikel der Ausgabe 1/2017

Acta Neuropathologica 1/2017 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.